<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992938</url>
  </required_header>
  <id_info>
    <org_study_id>803/16</org_study_id>
    <nct_id>NCT02992938</nct_id>
  </id_info>
  <brief_title>Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia</brief_title>
  <official_title>Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remifentanil is a potent opioid widely used during the administration of general anesthesia.
      There is a lot of evidence that suggest that the used of remifentanil is associated with the
      development of hyperalgesia (a reduction of nociceptive thresholds). However, the mechanism
      of this hyperalgesia is not fully understood.

      Recently, it was demonstrated that the disruption of the Cl- homeostasis could be involved.
      Interestingly, this was prevented in a murine model with the administration of Acetazolamide,
      a carbonic anhydrase inhibitor. In our clinical trial we will try to determine if the
      preoperative administration of acetazolamide could prevent the hyperalgesia induced by
      remifentanil in patients scheduled for thyroidectomy with general anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mechanical pain threshold in an area distant to the site of the injury</measure>
    <time_frame>12-18 hours after the end of the surgery</time_frame>
    <description>The threshold will be determine using von Frey monofilaments before the surgery and will be compared 12-18 hours after the end of the surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the mechanical pain threshold in an area distant to the site of the injury</measure>
    <time_frame>2 hours after the end of the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>The first postoperative day</time_frame>
    <description>A visual analogue scale (VAS; 0, no pain; 100, worst poss- ible pain) will be used to assess pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>The first postoperative day</time_frame>
    <description>Morphine consumption with a patient controlled analgesia (PCA) in mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hyperalgesia</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for thyroidectomy with general anesthesia in the University of
             Chile Clinical Hospital

        Exclusion Criteria:

          -  Patients ASA III y IV

          -  Chronic pain history

          -  Drug and alcohol abuse

          -  Chronic use of opioid and sedatives

          -  Neuropsychiatric illness

          -  NSAID and other analgesics used the 48 hours previous to the surgery

          -  CMI &gt; 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Gutierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia Department, University of Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonello Penna, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia Department, University of Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodrigo Gutierrez, MD</last_name>
    <phone>+56995993665</phone>
    <email>rggutierrez1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonello Penna, MD PhD</last_name>
    <phone>+56956756623</phone>
    <email>apennas@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, University of Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>7563215</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Gutierrez, MD</last_name>
      <phone>+56995993665</phone>
      <email>rggutierrez1@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <results_reference>
    <citation>Ferrini F, Trang T, Mattioli TA, Laffray S, Del'Guidice T, Lorenzo LE, Castonguay A, Doyon N, Zhang W, Godin AG, Mohr D, Beggs S, Vandal K, Beaulieu JM, Cahill CM, Salter MW, De Koninck Y. Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl⁻ homeostasis. Nat Neurosci. 2013 Feb;16(2):183-92. doi: 10.1038/nn.3295. Epub 2013 Jan 6.</citation>
    <PMID>23292683</PMID>
  </results_reference>
  <results_reference>
    <citation>Echevarría G, Elgueta F, Fierro C, Bugedo D, Faba G, Iñiguez-Cuadra R, Muñoz HR, Cortínez LI. Nitrous oxide (N(2)O) reduces postoperative opioid-induced hyperalgesia after remifentanil-propofol anaesthesia in humans. Br J Anaesth. 2011 Dec;107(6):959-65. doi: 10.1093/bja/aer323. Epub 2011 Sep 28.</citation>
    <PMID>21965050</PMID>
  </results_reference>
  <results_reference>
    <citation>Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003 Nov;106(1-2):49-57.</citation>
    <PMID>14581110</PMID>
  </results_reference>
  <results_reference>
    <citation>Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, Chauvin M. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005 Jul;103(1):147-55.</citation>
    <PMID>15983467</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>January 29, 2017</last_update_submitted>
  <last_update_submitted_qc>January 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Rodrigo Gutiérrez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Opioid hyperalgesia</keyword>
  <keyword>Acetazolamide</keyword>
  <keyword>Remifentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

